[Pubmed] Correlation Between MG Symptoms PRO and Existing MG-Specific Outcome Scores in the Phase 3 MycarinG Study: Post

[RSS-Bot]

Neurology. 2025 Apr 8;104(7_Supplement_1):1865. doi: 10.1212/WNL.0000000000208794. Epub 2025 Apr 7.

ABSTRACT

OBJECTIVE: To evaluate the correlation between Myasthenia Gravis (MG) Symptoms Patient-Reported Outcome (MG Symptoms PRO) scale scores and MG Activities of Daily Living (MG-ADL) and Quantitative MG (QMG) subdomain scores using data from the Phase 3 MycarinG study (NCT03971422) of rozanolixizumab in patients with generalized MG.

BACKGROUND: MG Symptoms PRO is a novel tool comprising five independent scales to measure MG symptoms: Muscle Weakness Fatigability, Physical Fatigue, Bulbar Muscle Weakness, Ocular Muscle Weakness and Respiratory Muscle Weakness.

DESIGN/METHODS: In MycarinG, patients were randomly assigned 1:1:1 to once-weekly subcutaneous rozanolixizumab 7 mg/kg, 10 mg/kg or placebo for 6 weeks. Outcome assessments included changes in MG-ADL (primary endpoint at Day 43), QMG and three MG Symptoms PRO scales. This post hoc analysis used MycarinG baseline scores (prior to treatment) to evaluate the correlation between MG Symptoms PRO scales and subdomains of MG-ADL and QMG scores (ocular, bulbar, respiratory and limb weakness/gross motor), using the Pearson coefficient between each pair of scores (strong: ≥0.7; moderate: 0.5-

Source: https://pubmed.ncbi.nlm.nih.gov/4019411 ... t9+e462414